Clinical trials: Vaccination; Infection
RSV Infection
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults
A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN®-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model…
- Trial name
- NCT04752644
- Testing
- MVA-mBN294B
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Influenza
Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin
There is an obvious need for an affordable and more effective seasonal influenza vaccine. TETRALITE is a novel, inactivated, adjuvanted influenza vaccine combining a low dose of a licensed vaccine with the novel, potent LiteVax…
- Trial name
- TETRALITE-I (NCT05581407)
- Testing
- TETRALITE
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Hepatitis B Vaccine
Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.
The purpose of this study is to assess the persistence of immunity to hepatitis B in children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy.
- Trial name
- NCT00519649
- Testing
- Engerix™-B Kinder
- Where
- 35 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety of the inactivated, split-virion influenza vaccine, 2008-2009 formulation. To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine 2008-2009 formulation…
- Trial name
- NCT00743275
- Testing
- Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
The purpose of this study is 1) to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs) and 2) to evaluate the anti-pneumococcal polysaccharide (PnPs)…
- Trial name
- PNEU-PLAN (NCT03885934)
- Testing
- V114, Prevnar 13®
- Where
- 26 sites in Finland, Malaysia and 3 more
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Disease
Safety of MenACWY-CRM Vaccination in Adolescents
The purpose of this US FDA post-marketing commitment study is to evaluate the safety of MenACWY-CRM among 50.000 vaccinated adolescents within a large US Healthcare Maintenance Organization who received MenACWY-CRM vaccination as…
- Trial name
- NCT01452464
- Testing
- MenACWY-CRM
- Where
- 3 sites in United States
- Volunteers
- 55,397 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine
The proposed study V72P9E1 is an Extension Study of V72P9. The objectives of this extension study will be to explore antibody persistence in children at approximately 40 months of age and to evaluate the safety, tolerability and…
- Trial name
- NCT01026974
- Testing
- rMenB, rMenB+OMV NZ
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hepatitis B, Diphtheria
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
This study will assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared to the separate administration of DTPa-HBV-IPV…
- Conditions
- Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib), Poliomyelitis
- Trial name
- NCT01457495
- Testing
- DTPa-HBV-IPV/Hib (Infanrix-hexa™), DTPa-IPV/Hib (Infanrix-IPV/Hib™), HBV (Engerix™-B)
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smallpox
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
- Trial name
- NCT00053495
- Testing
- Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax
- Where
- 4 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Infections, Streptococcal
A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study
Evaluate lot-to-lot consistency, safety and reactogenicity of 3 doses of GSK Biologicals' 10-valent pneumococcal conjugate vaccine and non-inferiority with respect to Prevenar.
- Trial name
- NCT00307554
- Testing
- Pneumococcal (vaccine)
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP)…
- Trial name
- NCT05581641
- Testing
- BNT165b1
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Staphylococcal Infections
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus…
- Trial name
- NCT01643941
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 7 sites in United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.
- Trial name
- NCT00192218
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 3,022 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Infant, Healthy
Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®
The purpose of the study is to provide data on the safety and immunogenicity of Pediacel® to allow its use as a fourth dose administered to 11-18 months old toddlers at the same time as Prevenar®.
- Trial name
- NCT00355654
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, DT3aP-HBs-IPV
- Where
- 84 sites in Germany
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV/AIDS, HIV Infections
Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)
Pre-Exposure Prophylaxis (PrEP) is a biomedical strategy consisting of the use of antiretroviral therapy by HIV-seronegative people at high risk of acquiring HIV, to prevent the infection.
- Conditions
- HIV/AIDS, HIV Infections, Sexually Transmitted Diseases, Vaccination
- Trial name
- seguiPrEP (NCT03996941)
- Testing
- Harm reduction of informal PrEP use, PrEP follow up based on point of care testing
- Where
- Spain
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- BCN Checkpoint
Encephalitis, Tick-borne
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN NEW (5 consecutive lots) in comparison to…
- Trial name
- NCT00161824
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Poland
- Volunteers
- 3,800 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
This is a non-randomized, open-label, externally controlled study to evaluate the safety and immnunogenicity of the Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above with no vaccination…
- Trial name
- COVID-19 (NCT05365724)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Asthma
Varicella Vaccination With Pulmicort
A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine
- Trial name
- NCT00641446
- Testing
- budesonide, varicella zoster virus
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH